NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
The early success of an experimental drug from Bristol-Myers Squibb Co. that's designed to unleash the body's immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.
Bristol-Myers Squibb announced this week that not one but two of its experimental immunotherapy drugs, not chemotherapy drugs, immunotherapy, have shown amazing results in advanced stages of several types of cancer, and the results are long lasting.
Drugmaker Bristol-Myers Squibb Co (BMY.N) on Tuesday said its board authorized the repurchase of $3 billion of the company's common stock in addition to the $3 billion share buyback program it announced in 2010.